Federico Cappuzzo
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 211
- Lung Cancer Diagnosis and Treatment 51
- Gastric Cancer Management and Outcomes 16
- Oncology 208
- Colorectal Cancer Treatments and Studies 72
- Cancer Immunotherapy and Biomarkers 71
- Lung Cancer Research Studies 67
- HER2/EGFR in Cancer Research 25
- Co-authors
- Tony Mok (35 shared papers)Pasi A. Jänne (13 shared papers)Lucio Crinò (62 shared papers)Marileila Varella‐Garcia (29 shared papers)Tarek Mekhail (11 shared papers)Robert M. Jotte (26 shared papers)Marcin Kowanetz (8 shared papers)Luca Toschi (28 shared papers)
- Journals
- Journal of Clinical Oncology (65 papers)Annals of Oncology (47 papers)Journal of Thoracic Oncology (39 papers)Lung Cancer (24 papers)British Journal of Cancer (10 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
Federico Cappuzzo
345 papers receiving 24.5k citations
Federico Cappuzzo's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 13.0k
- Pulmonary and Respiratory Medicine 13.6k
- Cancer Research 3.2k
- Hepatology 1.1k
- Molecular Biology 5.9k
Countries citing papers authored by Federico Cappuzzo
This map shows the geographic impact of Federico Cappuzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Cappuzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Cappuzzo more than expected).
Fields of papers citing papers by Federico Cappuzzo
This network shows the impact of papers produced by Federico Cappuzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Cappuzzo. The network helps show where Federico Cappuzzo may publish in the future.
Co-authors
The 25 scholars most cited alongside Federico Cappuzzo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 362 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3583 |
| 2 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2018 | 2686 |
| 3 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer Hit paper breakdown → | 2014 | 2349 |
| 4 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1170 |
| 5 | Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Hit paper breakdown → | 2010 | 920 |
| 6 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Hit paper breakdown → | 2019 | 698 |
| 7 | PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients Hit paper breakdown → | 2014 | 498 |
| 8 | Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients Hit paper breakdown → | 2009 | 458 |
| 9 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 420 |
| 10 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2021 | 338 |
| 11 | Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer Hit paper breakdown → | 2012 | 332 |
| 12 | 2004 | 310 | |
| 13 | 2005 | 304 | |
| 14 | 2005 | 299 | |
| 15 | 2018 | 287 | |
| 16 | 2004 | 277 | |
| 17 | Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Hit paper breakdown → | 2016 | 271 |
| 18 | 2008 | 255 | |
| 19 | 2007 | 231 | |
| 20 | 2010 | 228 |
About Federico Cappuzzo
Federico Cappuzzo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 362 papers that have together received 25.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (211 papers), Colorectal Cancer Treatments and Studies (72 papers), Cancer Immunotherapy and Biomarkers (71 papers), Lung Cancer Research Studies (67 papers), Lung Cancer Diagnosis and Treatment (51 papers), Cancer Genomics and Diagnostics (39 papers), HER2/EGFR in Cancer Research (25 papers) and Gastric Cancer Management and Outcomes (16 papers). The work is most often cited by research in Oncology (13.0k citations), Pulmonary and Respiratory Medicine (13.6k citations), Cancer Research (3.2k citations), Hepatology (1.1k citations) and Molecular Biology (5.9k citations). Federico Cappuzzo has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Tony Mok, Pasi A. Jänne, Lucio Crinò, Marileila Varella‐Garcia, Tarek Mekhail, Robert M. Jotte, Marcin Kowanetz, Luca Toschi, Stefania Bartolini and Delvys Rodríguez‐Abreu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.